Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Abstract Background Thymidine kinase 1 (TK1) is a cell cycle-regulated enzyme with peak expression in the S phase during DNA synthesis, and it is an attractive biomarker of cell proliferation. Serum TK1 activity has demonstrated prognostic value in patients with early-stage breast cancer. Because cy...

詳細記述

書誌詳細

主要な著者:	Nusayba Bagegni, Shana Thomas, Ning Liu, Jingqin Luo, Jeremy Hoog, Donald W. Northfelt, Matthew P. Goetz, Andres Forero, Mattias Bergqvist, Jakob Karen, Magnus Neumüller, Edward M. Suh, Zhanfang Guo, Kiran Vij, Souzan Sanati, Matthew Ellis, Cynthia X. Ma
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2017-11-01
シリーズ:	Breast Cancer Research
主題:	Breast cancer Thymidine kinase Palbociclib Anastrozole Neoadjuvant Biomarker
オンライン･アクセス:	http://link.springer.com/article/10.1186/s13058-017-0913-7
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!